The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
96
Mirabegron 50 mg/day will be administered for 14 weeks.
Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
Placebo will be administered for 14 weeks after baseline procedures.
University of Kentucky
Lexington, Kentucky, United States
RECRUITINGOral glucose tolerance test
Participants will complete a standard oral glucose tolerance test using 75 g of glucose at baseline and blood glucose will be measured.
Time frame: Baseline
Oral glucose tolerance test
Participants will complete a standard oral glucose tolerance test using 75 g of glucose at 14 weeks and blood glucose will be measured.
Time frame: 14 weeks
Hemoglobin A1C
Participant hemoglobin A1C will be evaluated at baseline.
Time frame: Baseline
Hemoglobin A1C
Participant hemoglobin A1C will be evaluated at 14 weeks.
Time frame: 14 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.